Oral Oncology
Volume 46, Issue 9 , Pages 648-653 , September 2010

Angiogenin-mediated ribosomal RNA transcription as a molecular target for treatment of head and neck squamous cell carcinoma

  • Lili Chen

      Affiliations

    • Department of Stomatology, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, China
    • Corresponding Author InformationCorresponding author.
    • ,
  • Guo-fu Hu

      Affiliations

    • Department of Pathology, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 617 432 6582; fax: +1 617 432 6580.

Received 9 June 2010 ,Revised 22 June 2010 ,Accepted 23 June 2010.

References 

  1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med. 1993;328:184–194
  2. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008;371:1695–1709
  3. Gillison ML, D’Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100:407–420
  4. Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357:2552–2561
  5. Olivier M, Petitjean A, Marcel V, et al. Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther. 2009;16:1–12
  6. Perez-Ordonez B, Beauchemin M, Jordan RC. Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol. 2006;59:445–453
  7. Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res. 2001;264:42–55
  8. Capaccio P, Pruneri G, Carboni N, et al. Cyclin D1 expression is predictive of occult metastases in head and neck cancer patients with clinically negative cervical lymph nodes. Head Neck. 2000;22:234–240
  9. Pignataro L, Pruneri G, Carboni N, et al. Clinical relevance of cyclin D1 protein overexpression in laryngeal squamous cell carcinoma. J Clin Oncol. 1998;16:3069–3077
  10. Chen Y, Chen C. DNA copy number variation and loss of heterozygosity in relation to recurrence of and survival from head and neck squamous cell carcinoma: a review. Head Neck. 2008;30:1361–1383
  11. Hasina R, Lingen MW. Angiogenesis in oral cancer. J Dent Educ. 2001;65:1282–1290
  12. Seiwert TY, Cohen EE. Targeting angiogenesis in head and neck cancer. Semin Oncol. 2008;35:274–285
  13. Klem ML, Mechalakos JG, Wolden SL, et al. Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy. Int J Radiat Oncol Biol Phys. 2008;70:1100–1107
  14. Lee NY, O’Meara W, Chan K, et al. Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys. 2007;69:459–468
  15. Goon PK, Stanley MA, Ebmeyer J, et al. HPV and head and neck cancer: a descriptive update. Head Neck Oncol. 2009;1:36
  16. Segal NH, Saltz LB. Evolving treatment of advanced colon cancer. Annu Rev Med. 2009;60:207–219
  17. Beasley NJ, Prevo R, Banerji S, et al. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res. 2002;62:1315–1320
  18. Beck L, D’Amore PA. Vascular development: cellular and molecular regulation. Faseb J. 1997;11:365–373
  19. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267:10931–10934
  20. Pepper MS. Manipulating angiogenesis. From basic science to the bedside. Arterioscler Thromb Vasc Biol. 1997;17:605–619
  21. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–257
  22. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999;284:1994–1998
  23. Moscatelli D, Rifkin DB. Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis. Biochim Biophys Acta. 1988;948:67–85
  24. Bussolino F, Mantovani A, Persico G. Molecular mechanisms of blood vessel formation. Trends Biochem Sci. 1997;22:251–256
  25. Nicosia RF, Villaschi S. Autoregulation of angiogenesis by cells of the vessel wall. Int Rev Cytol. 1999;185:1–43
  26. Hungerford JE, Little CD. Developmental biology of the vascular smooth muscle cell: building a multilayered vessel wall. J Vasc Res. 1999;36:2–27
  27. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353–364
  28. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995;333:1757–1763
  29. Thomas KA, Rios-Candelore M, Gimenez-Gallego G, et al. Pure brain-derived acidic fibroblast growth factor is a potent angiogenic vascular endothelial cell mitogen with sequence homology to interleukin 1. Proc Natl Acad Sci USA. 1985;82:6409–6413
  30. Fett JW, Olson KA, Rybak SM. A monoclonal antibody to human angiogenin. Inhibition of ribonucleolytic and angiogenic activities and localization of the antigenic epitope. Biochemistry. 1994;33:5421–5427
  31. Montesano R, Vassalli JD, Baird A, et al. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA. 1986;83:7297–7301
  32. Schreiber AB, Winkler ME, Derynck R. Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science. 1986;232:1250–1253
  33. Kozian DH, Ziche M, Augustin HG. The activin-binding protein follistatin regulates autocrine endothelial cell activity and induces angiogenesis. Lab Invest. 1997;76:267–276
  34. Sierra-Honigmann MR, Nath AK, Murakami C, et al. Biological action of leptin as an angiogenic factor. Science. 1998;281:1683–1686
  35. Fang W, Hartmann N, Chow DT, et al. Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer. J Biol Chem. 1992;267:25889–25897
  36. Ishikawa F, Miyazono K, Hellman U, et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature. 1989;338:557–562
  37. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306–1309
  38. Maglione D, Guerriero V, Viglietto G, et al. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA. 1991;88:9267–9271
  39. Bussolino F, Ziche M, Wang JM, et al. In vitro and in vivo activation of endothelial cells by colony-stimulating factors. J Clin Invest. 1991;87:986–995
  40. Risau W, Drexler H, Mironov V, et al. Platelet-derived growth factor is angiogenic in vivo. Growth Factors. 1992;7:261–266
  41. Montrucchio G, Lupia E, Battaglia E, et al. Tumor necrosis factor alpha-induced angiogenesis depends on in situ platelet-activating factor biosynthesis. J Exp Med. 1994;180:377–382
  42. Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 1992;258:1798–1801
  43. Jackson D, Volpert OV, Bouck N, Linzer DI. Stimulation and inhibition of angiogenesis by placental proliferin and proliferin-related protein. Science. 1994;266:1581–1584
  44. Albini A, Barillari G, Benelli R, et al. Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proc Natl Acad Sci USA. 1995;92:4838–4842
  45. Grant MB, Mames RN, Fitzgerald C, et al. Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor. Diabetologia. 1993;36:282–291
  46. Frater-Schroder M, Risau W, Hallmann R, et al. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA. 1987;84:5277–5281
  47. Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA. 1986;83:4167–4171
  48. Melese T, Xue Z. The nucleolus: an organelle formed by the act of building a ribosome. Curr Opin Cell Biol. 1995;7:319–324
  49. Ibaragi S, Yoshioka N, Kishikawa H, et al. Angiogenin-stimulated ribosomal RNA transcription is essential for initiation and survival of AKT-induced prostate intraepithelial neoplasia. Mol Cancer Res. 2009;7:415–424
  50. Kishimoto K, Liu S, Tsuji T, et al. Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene. 2005;24:445–456
  51. Tsuji T, Sun Y, Kishimoto K, et al. Angiogenin is translocated to the nucleus of HeLa cells and is involved in ribosomal RNA transcription and cell proliferation. Cancer Res. 2005;65:1352–1360
  52. Yoshioka N, Wang L, Kishimoto K, et al. A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation. Proc Natl Acad Sci USA. 2006;103:14519–14524
  53. Fett JW, Strydom DJ, Lobb RR, et al. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry. 1985;24:5480–5486
  54. Shapiro R, Riordan JF, Vallee BL. Characteristic ribonucleolytic activity of human angiogenin. Biochemistry. 1986;25:3527–3532
  55. Shapiro R, Vallee BL. Site-directed mutagenesis of histidine-13 and histidine-114 of human angiogenin. Alanine derivatives inhibit angiogenin-induced angiogenesis. Biochemistry. 1989;28:7401–7408
  56. Badet J, Soncin F, Guitton JD, et al. Specific binding of angiogenin to calf pulmonary artery endothelial cells. Proc Natl Acad Sci USA. 1989;86:8427–8431
  57. Hu GF, Riordan JF, Vallee BL. A putative angiogenin receptor in angiogenin-responsive human endothelial cells. Proc Natl Acad Sci USA. 1997;94:2204–2209
  58. Hu GF, Chang SI, Riordan JF, Vallee BL. An angiogenin-binding protein from endothelial cells. Proc Natl Acad Sci USA. 1991;88:2227–2231
  59. Hu GF, Riordan JF. Angiogenin enhances actin acceleration of plasminogen activation. Biochem Biophys Res Commun. 1993;197:682–687
  60. Hu G, Riordan JF, Vallee BL. Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities. Proc Natl Acad Sci USA. 1994;91:12096–12100
  61. Soncin F. Angiogenin supports endothelial and fibroblast cell adhesion. Proc Natl Acad Sci USA. 1992;89:2232–2236
  62. Jimi S, Ito K, Kohno K, et al. Modulation by bovine angiogenin of tubular morphogenesis and expression of plasminogen activator in bovine endothelial cells. Biochem Biophys Res Commun. 1995;211:476–483
  63. Moroianu J, Riordan JF. Nuclear translocation of angiogenin in proliferating endothelial cells is essential to its angiogenic activity. Proc Natl Acad Sci USA. 1994;91:1677–1681
  64. Li R, Riordan JF, Hu G. Nuclear translocation of human angiogenin in cultured human umbilical artery endothelial cells is microtubule and lysosome independent. Biochem Biophys Res Commun. 1997;238:305–312
  65. Hu GF. Neomycin inhibits angiogenin-induced angiogenesis. Proc Natl Acad Sci USA. 1998;95:9791–9795
  66. Xu ZP, Tsuji T, Riordan JF, Hu GF. The nuclear function of angiogenin in endothelial cells is related to rRNA production. Biochem Biophys Res Commun. 2002;294:287–292
  67. Xu ZP, Tsuji T, Riordan JF, Hu GF. Identification and characterization of an angiogenin-binding DNA sequence that stimulates luciferase reporter gene expression. Biochemistry. 2003;42:121–128
  68. Clarke EM, Peterson CL, Brainard AV, Riggs DL. Regulation of the RNA polymerase I and III transcription systems in response to growth conditions. J Biol Chem. 1996;271:22189–22195
  69. Baxter GC, Stanners CP. The effect of protein degradation on cellular growth characteristics. J Cell Physiol. 1978;96:139–145
  70. Hirukawa S, Olson KA, Tsuji T, Hu GF. Neamine inhibits xenografic human tumor growth and angiogenesis in athymic mice. Clin Cancer Res. 2005;11:8745–8752
  71. Hu G, Xu C, Riordan JF. Human angiogenin is rapidly translocated to the nucleus of human umbilical vein endothelial cells and binds to DNA. J Cell Biochem. 2000;76:452–462
  72. Ibaragi S, Yoshioka N, Li S, et al. Neamine inhibits prostate cancer growth by suppressing angiogenin-mediated ribosomal RNA transcription. Clin Cancer Res. 2009;15:1981–1988
  73. Eberle K, Oberpichler A, Trantakis C, et al. The expression of angiogenin in tissue samples of different brain tumours and cultured glioma cells. Anticancer Res. 2000;20:1679–1684
  74. Montero S, Guzman C, Cortes-Funes H, Colomer R. Angiogenin expression and prognosis in primary breast carcinoma. Clin Cancer Res. 1998;4:2161–2168
  75. Bodner-Adler B, Hefler L, Bodner K, et al. Serum levels of angiogenin (ANG) in invasive cervical cancer and in cervical intraepithelial neoplasia (CIN). Anticancer Res. 2001;21:809–812
  76. Li D, Bell J, Brown A, Berry CL. The observation of angiogenin and basic fibroblast growth factor gene expression in human colonic adenocarcinomas, gastric adenocarcinomas, and hepatocellular carcinomas. J Pathol. 1994;172:171–175
  77. Shimoyama S, Shimizu N, Tsuji E, et al. Distribution of angiogenin and its gene message in colorectal cancer patients and their clinical relevance. Anticancer Res. 2002;22:1045–1052
  78. Chopra V, Dinh TV, Hannigan EV. Serum levels of interleukins, growth factors and angiogenin in patients with endometrial cancer. J Cancer Res Clin Oncol. 1997;123:167–172
  79. Shimoyama S, Kaminishi M. Increased angiogenin expression in gastric cancer correlated with cancer progression. J Cancer Res Clin Oncol. 2000;126:468–474
  80. Chopra V, Dinh TV, Hannigan EV. Production of angiogenic factors by in vitro cultured tumor cells and peripheral blood mononuclear cells from patients with gynecological cancers. Proc Annu Meet Am Assoc Cancer Res. 1995;36:A516
  81. Homer JJ, Greenman J, Stafford ND. Angiogenic cytokines in serum and plasma of patients with head and neck squamous cell carcimona. Clin Otolaryngol Allied Sci. 2000;25:570–576
  82. Homer JJ, Greenman J, Stafford ND. Circulating angiogenic cytokines as tumour markers and prognostic factors in head and neck squamous cell carcinoma. Clin Otolaryngol. 2002;27:32–37
  83. Kim SM, Myoung H, Choung PH, et al. Metastatic leiomyosarcoma in the oral cavity: case report with protein expression profiles. J Craniomaxillofac Surg. 2009;37:454–460
  84. Park YW, Kim SM, Min BG, et al. Lymphangioma involving the mandible: immunohistochemical expressions for the lymphatic proliferation. J Oral Pathol Med. 2002;31:280–283
  85. Terpos E, Kastritis E, Roussou M, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia. 2008;22:2247–2256
  86. Brunner B, Gunsilius E, Schumacher P, et al. Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. J Hematother Stem Cell Res. 2002;11:119–125
  87. Cregan SP, Fortin A, MacLaurin JG, et al. Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. J Cell Biol. 2002;158:507–517
  88. Bertolini F, Paolucci M, Peccatori F, et al. Angiogenic growth factors and endostatin in non-Hodgkin’s lymphoma. Br J Haematol. 1999;106:504–509
  89. Hartmann A, Kunz M, Kostlin S, et al. Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res. 1999;59:1578–1583
  90. Kushlinskii NE, Babkina IV, Solov’ev YN, Trapeznikov NN. Vascular endothelium growth factor and angiogenin in the serum of patients with osteosarcoma and Ewing’s tumor. Bull Exp Biol Med. 2000;130:691–693
  91. Barton DP, Cai A, Wendt K, et al. Angiogenic protein expression in advanced epithelial ovarian cancer. Clin Cancer Res. 1997;3:1579–1586
  92. Shimoyama S, Gansauge F, Gansauge S, et al. Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness. Cancer Res. 1996;56:2703–2706
  93. Katona TM, Neubauer BL, Iversen PW, et al. Elevated expression of angiogenin in prostate cancer and its precursors. Clin Cancer Res. 2005;11:8358–8363
  94. Wechsel HW, Bichler KH, Feil G, et al. Renal cell carcinoma: relevance of angiogenetic factors. Anticancer Res. 1999;19:1537–1540
  95. Miyake H, Hara I, Yamanaka K, et al. Increased angiogenin expression in the tumor tissue and serum of urothelial carcinoma patients is related to disease progression and recurrence. Cancer. 1999;86:316–324
  96. Skoldenberg EG, Christiansson J, Sandstedt B, et al. Angiogenesis and angiogenic growth factors in Wilms tumor. J Urol. 2001;165:2274–2279
  97. Kao RY, Jenkins JL, Olson KA, et al. A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity. Proc Natl Acad Sci USA. 2002;99:10066–10071
  98. Olson KA, Byers HR, Key ME, Fett JW. Prevention of human prostate tumor metastasis in athymic mice by antisense targeting of human angiogenin. Clin Cancer Res. 2001;7:3598–3605
  99. Olson KA, Byers HR, Key ME, Fett JW. Inhibition of prostate carcinoma establishment and metastatic growth in mice by an antiangiogenin monoclonal antibody. Int J Cancer. 2002;98:923–929
  100. Olson KA, Fett JW, French TC, et al. Angiogenin antagonists prevent tumor growth in vivo. Proc Natl Acad Sci USA. 1995;92:442–446
  101. Chien CY, Su CY, Hwang CF, et al. High expressions of CD105 and VEGF in early oral cancer predict potential cervical metastasis. J Surg Oncol. 2006;94:413–417
  102. Jablonska E, Piotrowski L, Jablonski J, Grabowska Z. VEGF in the culture of PMN and the serum in oral cavity cancer patients. Oral Oncol. 2002;38:605–609
  103. Matsuura M, Onimaru M, Yonemitsu Y, et al. Autocrine loop between vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 positively regulates tumor-associated lymphangiogenesis in oral squamoid cancer cells. Am J Pathol. 2009;175:1709–1721
  104. Okada Y, Ueno H, Katagiri M, et al. Experimental study of antiangiogenic gene therapy targeting VEGF in oral cancer. Odontology. 2010;98:52–59
  105. Siriwardena BS, Kudo Y, Ogawa I, et al. VEGF-C is associated with lymphatic status and invasion in oral cancer. J Clin Pathol. 2008;61:103–108
  106. Strauss L, Volland D, Kunkel M, Reichert TE. Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angiogenesis and immune tolerance. Med Sci Monit. 2005;11:BR280–BR292
  107. Weiner HL, Weiner LH, Swain JL. Tissue distribution and developmental expression of the messenger RNA encoding angiogenin. Science. 1987;237:280–282
  108. Hatzi E, Bassaglia Y, Badet J. Internalization and processing of human angiogenin by cultured aortic smooth muscle cells. Biochem Biophys Res Commun. 2000;267:719–725
  109. Waksman SA, Lechevalier HA. Neomycin, a new antibiotic active against streptomycin-resistant bacteria, including tuberculosis organisms. Science. 1949;109:305–307
  110. Glasby JS. Encyclopedia of antibiotics. 3rd ed.. New York, NY: John Wiley and Sons Ltd; 1993;p. 363–7
  111. Williams PD, Bennett DB, Gleason CR, Hottendorf GH. Correlation between renal membrane binding and nephrotoxicity of aminoglycosides. Antimicrob Agents Chemother. 1987;31:570–574
  112. Leach BE, Teeters CM. Neamine, an antibacterial degradation product of neomycin. J Am Chem Soc. 1951;73:2794–2797
  113. Au S, Weiner N, Schacht J. Membrane perturbation by aminoglycosides as a simple screen of their toxicity. Antimicrob Agents Chemother. 1986;30:395–397
  114. Wintrobe M, Thorn G, Adams R, et al. Harrison’s principles of internal medicine. 6th ed.. New York: McGraw-Hill; 1971;p. 749
  115. Anderson WF, Hawk E, Berg CD. Secondary chemoprevention of upper aerodigestive tract tumors. Semin Oncol. 2001;28:106–120

PII: S1368-8375(10)00195-8

doi: 10.1016/j.oraloncology.2010.06.011

Oral Oncology
Volume 46, Issue 9 , Pages 648-653 , September 2010

Article Tools